Posters
(results will display both Free Papers & Poster)
Ocular findings in patients with systemic sclerosis
Poster Details
First Author: N.Kocak TURKEY
Co Author(s): M. Kaya M. Birlik T. Ozturk O. Donmez Z. Ayhan S. Kaynak
Abstract Details
Purpose:
To determine the common ocular findings in patients with systemic sclerosis (SS).
Setting:
Dokuz Eylul University, Department of Ophthalmology
Dokuz Eylul University, Department of Rheumatology
Methods:
A hundred eyes of 50 consecutive patients with SS were enrolled. Cases with diabetes, hypertension, mixed connective tissue disease, renal crisis, and pulmonary hypertension were excluded. Study population was divided into two subgroups as limited-SS and diffuse-SS. Patient demographics, disease duration, serum antibody profiles, and medications were noted for each participants. Detailed ophthalmologic examinations including corneal topography and optical coherence tomography was performed in all cases. Student t and Mann-Whitney U tests were used for statistics.
Results:
Mean age was 53.0±10.5 years (range, 32-69 years) and the disease duration was 9.7±7.6 years (range, 2-33 years). Fourtyfive cases (90%) were female. Sjogren's syndrome was diagnosed in 15 cases (30%) with limited-SS and 5 cases (10%) with diffuse-SS (p=0.005). Lid abnormalities were present in 48 eyes (48%). Keratoconjunctivitis sicca (KCS) was diagnosed in 59 eyes (59%). Lid abnormalities were observed more frequently in cases with diffuse-SS (p=0.001). There was no statistical difference in the incidence of KCS between two study subgroups (p=0.187). No statistically difference was found in central corneal thickness, central macular thickness and choroidal thickness between two study subgroups (p=0.645, p=659, and p=0.359, respectively).
Conclusions:
Lid abnormalities (telengiectasia, blepharophimosis, shortening of the fornices, and eyelid induration) and KCS were the most common ocular findings in cases with SS. Lid abnormalities were more frequently seen in cases with diffuse subtype of disease.
Financial Disclosure:
NONE